259 related articles for article (PubMed ID: 26077887)
1. Clinical significance of glycoprotein nonmetastatic B and its association with HER2 in breast cancer.
Kanematsu M; Futamura M; Takata M; Gaowa S; Yamada A; Morimitsu K; Morikawa A; Mori R; Hara H; Yoshida K
Cancer Med; 2015 Sep; 4(9):1344-55. PubMed ID: 26077887
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
3. GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer.
Bhat RR; Yadav P; Sahay D; Bhargava DK; Creighton CJ; Yazdanfard S; Al-Rawi A; Yadav V; Qin L; Nanda S; Sethunath V; Fu X; De Angelis C; Narkar VA; Osborne CK; Schiff R; Trivedi MV
Breast Cancer Res Treat; 2018 Jul; 170(2):279-292. PubMed ID: 29574636
[TBL] [Abstract][Full Text] [Related]
4. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
[TBL] [Abstract][Full Text] [Related]
5. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
[TBL] [Abstract][Full Text] [Related]
6. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.
Rose AA; Grosset AA; Dong Z; Russo C; Macdonald PA; Bertos NR; St-Pierre Y; Simantov R; Hallett M; Park M; Gaboury L; Siegel PM
Clin Cancer Res; 2010 Apr; 16(7):2147-56. PubMed ID: 20215530
[TBL] [Abstract][Full Text] [Related]
7. Junctional adhesion molecule-A is co-expressed with HER2 in breast tumors and acts as a novel regulator of HER2 protein degradation and signaling.
Brennan K; McSherry EA; Hudson L; Kay EW; Hill AD; Young LS; Hopkins AM
Oncogene; 2013 May; 32(22):2799-804. PubMed ID: 22751120
[TBL] [Abstract][Full Text] [Related]
8. Clinical Significance of Glycoprotein Non-metastatic B and Its Association with EGFR/HER2 in Gastrointestinal Cancer.
Tajima JY; Futamura M; Gaowa S; Mori R; Tanahashi T; Tanaka Y; Matsuhashi N; Takahashi T; Yamaguchi K; Miyazaki T; Yoshida K
J Cancer; 2018; 9(2):358-366. PubMed ID: 29344282
[TBL] [Abstract][Full Text] [Related]
9. HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss.
Bartel CA; Jackson MW
PLoS One; 2017; 12(5):e0176778. PubMed ID: 28463969
[TBL] [Abstract][Full Text] [Related]
10. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
12. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
13. High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.
Rhee J; Han SW; Cha Y; Ham HS; Kim HP; Oh DY; Im SA; Park JW; Ro J; Lee KS; Park IH; Im YH; Bang YJ; Kim TY
Breast Cancer Res Treat; 2011 Jan; 125(1):107-14. PubMed ID: 20936340
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
15. The Transmodulation of HER2 and EGFR by Substance P in Breast Cancer Cells Requires c-Src and Metalloproteinase Activation.
Garcia-Recio S; Pastor-Arroyo EM; Marín-Aguilera M; Almendro V; Gascón P
PLoS One; 2015; 10(6):e0129661. PubMed ID: 26114632
[TBL] [Abstract][Full Text] [Related]
16. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
18. GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin α5β1 for efficient breast cancer metastasis.
Maric G; Annis MG; Dong Z; Rose AA; Ng S; Perkins D; MacDonald PA; Ouellet V; Russo C; Siegel PM
Oncogene; 2015 Oct; 34(43):5494-504. PubMed ID: 25772243
[TBL] [Abstract][Full Text] [Related]
19. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
20. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G
Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]